Johnson & Johnson (JNJ) said Monday it plans to bolster its lineup of stroke-prevention products by buying Micrus Endovascular Corp. (MEND) for about $480 million, marking the latest deal in a neurovascular-device market that appears to be heating up.
J&J's planned purchase of San Jose, Calif.-based Micrus comes weeks after rival Covidien PLC (COV) announced plans to buy ev3 Corp. (EVVV), a Micrus rival, for $2.6 billion. Leerink Swann analyst Rick Wise said the Covidien-ev3 combination may have spurred on J&J due to a hospital-purchasing trend of focusing more on ...




: Great to share nice ideas. ------------ ...
: Great article! Excellent points made. Thanks!...
Drue De Angelis: The overarching theme from the halls of JP Morgan was that the capital...
Treating Scoliosis: Advances in scoliosis treatment have been monumental. Although, surge...
Diane Siriani: Interesting information! ...